Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
AGRX Agile Therapeutics, Inc. daily Stock Chart
AGRX [NASD]
Agile Therapeutics, Inc.
Healthcare | Drugs - Generic | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.50 Insider Own1.00% Shs Outstand45.32M Perf Week-5.67%
Market Cap60.28M Forward P/E- EPS next Y-0.43 Insider Trans11.02% Shs Float43.19M Perf Month-11.33%
Income-17.60M PEG- EPS next Q-0.11 Inst Own55.20% Short Float1.78% Perf Quarter42.41%
Sales- P/S- EPS this Y37.00% Inst Trans55.59% Short Ratio1.80 Perf Half Y50.28%
Book/sh0.66 P/B2.02 EPS next Y0.00% ROA-60.40% Target Price3.50 Perf Year116.26%
Cash/sh0.26 P/C5.20 EPS next 5Y- ROE-74.70% 52W Range0.23 - 1.70 Perf YTD130.94%
Dividend- P/FCF- EPS past 5Y11.00% ROI- 52W High-21.76% Beta0.50
Dividend %- Quick Ratio8.90 Sales past 5Y- Gross Margin- 52W Low475.76% ATR0.08
Employees13 Current Ratio8.90 Sales Q/Q- Oper. Margin- RSI (14)35.49 Volatility7.51% 5.98%
OptionableYes Debt/Eq0.00 EPS Q/Q37.30% Profit Margin- Rel Volume0.26 Prev Close1.33
ShortableYes LT Debt/Eq0.00 EarningsMar 18 AMC Payout- Avg Volume425.11K Price1.33
Recom2.00 SMA20-7.45% SMA50-9.99% SMA20047.53% Volume111,235 Change0.00%
Apr-12-19Resumed Janney Buy $4
Nov-29-18Initiated Maxim Group Buy $3
Dec-26-17Downgrade William Blair Outperform → Mkt Perform
Dec-26-17Downgrade Janney Buy → Neutral
Oct-02-17Resumed H.C. Wainwright Buy $10
Sep-14-17Reiterated RBC Capital Mkts Outperform $8 → $10
Jul-19-17Initiated H.C. Wainwright Buy $10
Jan-08-16Initiated Cantor Fitzgerald Buy
Apr-02-15Initiated FBR Capital Outperform $17
Jun-17-14Initiated William Blair Outperform
Jun-17-14Initiated RBC Capital Mkts Outperform $12
May-22-19 07:00AM  Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla® GlobeNewswire
May-17-19 07:30AM  Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch, Twirla® GlobeNewswire
May-09-19 08:00AM  Agile Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-03-19 08:00AM  Agile Therapeutics to Present Combined Safety Data from Three Phase 3 Studies at the 2019 ACOG Annual Meeting GlobeNewswire
May-02-19 06:56PM  Agile Therapeutics: 1Q Earnings Snapshot Associated Press
04:15PM  Agile Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
Mar-28-19 08:00AM  Agile Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in London, UK GlobeNewswire
Mar-15-19 08:00AM  Agile Therapeutics to Present In Vivo Adhesion Data from Two Phase 1 Studies at the 2nd Annual Formulation & Drug Delivery USA Congress GlobeNewswire
Mar-14-19 12:00PM  AGRX: Numerous Catalysts in 2019 Zacks Small Cap Research
Mar-12-19 05:52PM  Agile Therapeutics: 4Q Earnings Snapshot Associated Press +15.97%
04:15PM  Agile Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Mar-11-19 08:00AM  Agile Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire +26.32%
Mar-04-19 07:30AM  Agile Therapeutics Announces $7.8 Million Private Placement GlobeNewswire +19.70%
Feb-12-19 10:30AM  AGRX: Positive Results for Twirla® Adhesion Study; NDA Resubmission in 2Q19 Zacks Small Cap Research +9.37%
Feb-11-19 07:30AM  Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane® GlobeNewswire
Feb-07-19 08:00AM  Agile Therapeutics to Present at the 2019 BIO CEO and Investor Conference GlobeNewswire
Jan-11-19 10:45AM  AGRX: Twirla® Adhesion Study Underway; NDA Resubmission in 2Q19 Zacks Small Cap Research
08:38AM  The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA Benzinga
Jan-10-19 04:15PM  Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance GlobeNewswire
Dec-27-18 07:25AM  Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Dec-18-18 08:00AM  Agile Therapeutics to Present at Biotech Showcase 2019 GlobeNewswire -10.77%
Dec-13-18 04:15PM  Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane® GlobeNewswire
Nov-13-18 01:32PM  Agile Therapeutics Inc (NASDAQ:AGRX): Are Analysts Optimistic? Simply Wall St.
Nov-05-18 01:30PM  AGRX: Awaiting Details of Adhesion Study for Twirla® Zacks Small Cap Research
Nov-02-18 05:12AM  Agile Therapeutics: 3Q Earnings Snapshot Associated Press +13.82%
Nov-01-18 04:15PM  Agile Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire +9.72%
Oct-24-18 08:00AM  Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 (Twirla®) Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning (NAFFP) GlobeNewswire
Oct-23-18 08:25AM  New Research Coverage Highlights MEDIFAST INC, Palo Alto Networks, Salesforce, Agile Therapeutics, Dicerna Pharmaceuticals, and Corbus Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-22-18 08:15AM  Agile Therapeutics Gets a Path Forward for Twirla, Analysts Review and Target ACCESSWIRE -15.20%
Oct-16-18 08:00AM  Todays Research Reports on Stocks to Watch: Auris Medical Holding and Agile Therapeutics ACCESSWIRE
Oct-10-18 11:15AM  AGRX: FDA Provides Path to NDA Resubmission for Twirla® Zacks Small Cap Research -7.63%
08:00AM  Today's Research Reports on Trending Tickers: Agile Therapeutics and Horizon Pharma ACCESSWIRE
Oct-09-18 08:00AM  Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA GlobeNewswire +53.71%
Sep-14-18 10:04AM  Does Agile Therapeutics Inc (NASDAQ:AGRX) Fall With The Market? Simply Wall St. -25.36%
Sep-12-18 08:00AM  Todays Research Reports on Stocks to Watch: Agile Therapeutics and BioPharmX ACCESSWIRE -17.91%
Sep-11-18 10:35AM  New Growth Opportunities Jump for 3 Biotech Stocks in 2018 ACCESSWIRE +116.83%
Aug-29-18 08:10AM  Consolidated Research: 2018 Summary Expectations for Internap, Approach Resources, Agile Therapeutics, Town Sports International, Dicerna Pharmaceuticals, and Cott Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-09-18 09:45AM  AGRX: Formal Dispute Resolution Continues to Office of New Drugs Zacks Small Cap Research -5.32%
Aug-03-18 08:11AM  Agile Therapeutics: 2Q Earnings Snapshot Associated Press +8.58%
08:00AM  Agile Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-31-18 07:10AM  Complimentary Technical Snapshots on Akorn and Three More Generic Drugs Stocks ACCESSWIRE
Jul-24-18 04:10PM  FDAs Office of Drug Evaluation III Denies Agile Therapeutics, Inc.s Initial Formal Dispute Resolution Request GlobeNewswire
Jun-25-18 07:10AM  Free Technical Research on Akorn and Three More Generic Drugs Equities ACCESSWIRE
Jun-08-18 02:10PM  AGRX: Files Formal Dispute Resolution with the FDA Zacks Small Cap Research
09:20AM  Benzinga's Daily Biotech Pulse: EDAP Device Gets FDA Nod, Ampliphi Presents Positive Data, Agile To Cut Jobs Benzinga
Jun-07-18 04:10PM  Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance GlobeNewswire
May-22-18 09:25AM  AGRX: Determining a Path Forward Following Receipt of Meeting Minutes Zacks Small Cap Research
May-21-18 08:00AM  Todays Research Reports on Stocks to Watch: Agile Therapeutics and Arrowhead Pharmaceuticals ACCESSWIRE
May-18-18 10:44AM  Agile Therapeutics sinks after FDA feedback on contraceptive Reuters -72.40%
08:10AM  Consolidated Research: 2018 Summary Expectations for Verint, Mesabi Trust, Clearwater Paper, Agile Therapeutics, Community Trust, and Layne Christensen Fundamental Analysis, Key Performance Indications GlobeNewswire
07:51AM  Agile Therapeutics exploring funding options after FDA meeting Reuters
07:30AM  Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of Pregnancy GlobeNewswire
May-15-18 01:51PM  Corium International (CORI) Q2 2018 Earnings Conference Call Transcript Motley Fool
May-14-18 11:55AM  AGRX: Waiting on Meeting Minutes from FDA; Planning for 2Q18 Twirla® NDA Resubmission Zacks Small Cap Research
May-11-18 06:51PM  Have Investors Priced In Agile Therapeutics Incs (NASDAQ:AGRX) Growth? Simply Wall St.
May-07-18 04:38PM  Agile Therapeutics: 1Q Earnings Snapshot Associated Press +6.62%
04:10PM  Agile Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 08:58PM  When Can We Expect A Profit From Agile Therapeutics Inc (NASDAQ:AGRX)? Simply Wall St.
Mar-30-18 08:00AM  [$$] 3 Biotech Stocks a Pro Is Buying Now Barrons.com
Mar-28-18 03:28PM  What Should Investors Know About Agile Therapeutics Incs (NASDAQ:AGRX) Long Term Outlook? Simply Wall St. -9.36%
Mar-23-18 07:30AM  New Research: Key Drivers of Growth for At Home Group, Griffon, Mitek, J & J Snack Foods, Lindsay, and Agile Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-20-18 12:30PM  Is Agile Therapeutics Incs (NASDAQ:AGRX) Balance Sheet A Threat To Its Future? Simply Wall St.
Mar-14-18 07:45AM  Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition GlobeNewswire
Mar-12-18 05:25PM  Agile Therapeutics reports 4Q loss Associated Press
04:15PM  Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Jan-24-18 07:40AM  New Research Coverage Highlights Oracle, General Dynamics, Agile Therapeutics, Fidelity Southern, Syros Pharmaceuticals, and MSA Safety Incorporated Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Dec-27-17 11:19AM  Analyst Remains Confident In Corium Despite Partner's Bad FDA News Benzinga
Dec-22-17 11:23AM  Agile stock craters after FDA declines to approve contraceptive patch for second time MarketWatch -47.06%
08:05AM  Agile Therapeutics plunges toward record low after FDA rejects contraceptive patch's NDA MarketWatch
07:42AM  FDA declines to approve Agile's contraceptive patch Reuters
07:30AM  Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy GlobeNewswire
Dec-21-17 10:55AM  Who Are The Largest Shareholders In Agile Therapeutics Inc (NASDAQ:AGRX)? Simply Wall St.
Dec-08-17 07:58AM  With FDA Approvals in Sight, Will Synergy Pharmaceuticals and Agile Therapeutics Skyrocket as H.C Wainwright Predicts? SmarterAnalyst
Dec-01-17 02:20PM  Is It Too Late To Buy Agile Therapeutics Inc (AGRX)? Simply Wall St.
Nov-17-17 09:13AM  Corium Q4 Sales Top Expectations Ahead Of Slew Of Near-Term Catalysts Benzinga
Nov-15-17 02:17PM  What Investors Should Know About Agile Therapeutics Incs (AGRX) Financial Strength Simply Wall St.
Nov-08-17 11:30AM  AGRX: Countdown to Dec. 26, 2017 PDUFA for Twirla® Zacks Small Cap Research
Nov-06-17 04:25PM  Agile Therapeutics reports 3Q loss Associated Press
04:20PM  Agile Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-31-17 07:45AM  Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2017 PR Newswire +5.32%
Oct-25-17 11:36AM  3 Biotech Stocks to Consider Ahead of FDA Decisions Investopedia
Oct-16-17 07:45AM  Agile Therapeutics Presents Additional Twirla® Phase 3 SECURE Study Results at NAFFP 2017 PR Newswire
Oct-13-17 02:00PM  AGRX: Puts Forth Strong Case for Twirla® Ahead of PDUFA on Dec. 26, 2017 Zacks Small Cap Research -5.46%
Oct-02-17 07:30AM  Agile Therapeutics to Host First Analyst Day on October 10, 2017 GlobeNewswire +8.97%
Sep-28-17 07:45AM  Agile Therapeutics to Present Additional Phase 3 Data at the North American Forum on Family Planning Annual Meeting GlobeNewswire
Sep-14-17 07:45AM  Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire +7.43%
Sep-07-17 07:50AM  Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine GlobeNewswire
Aug-22-17 07:30AM  Agile Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-16-17 04:10PM  Agile Therapeutics to Present at Liolios 6th Annual Gateway Conference GlobeNewswire
Aug-10-17 02:00PM  AGRX: Raises $18.3 Million in Public Offering Zacks Small Cap Research
Aug-03-17 10:35AM  Agile Therapeutics Tanks on Secondary Offering 24/7 Wall St. -27.79%
08:24AM  Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock GlobeNewswire
Aug-02-17 04:05PM  Agile Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
Jul-31-17 11:00AM  AGRX: NDA for Twirla® Accepted by FDA; PDUFA is Dec. 26, 2017 Zacks Small Cap Research
Jul-28-17 10:58PM  Agile Therapeutics reports 2Q loss Associated Press +7.61%
07:30AM  Agile Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Jul-27-17 04:12PM  Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla® GlobeNewswire
Jun-28-17 06:00PM  AGRX: NDA for Twirla® Filed with FDA; Six Month Review Time Expected Zacks Small Cap Research
Jun-27-17 08:00AM  Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla® GlobeNewswire
May-15-17 12:00PM  AGRX: Initiating Coverage of Agile Therapeutics; NDA for Weekly Contraceptive Patch Set to Be Filed Zacks Small Cap Research
Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lele Abhijeet JDirectorMar 29Buy1.5420,00030,80037,949Apr 01 05:00 PM
ALTOMARI ALFREDChief Executive OfficerMar 25Buy1.5425,00038,500238,568Mar 26 05:00 PM
PERCEPTIVE ADVISORS LLCFormer 10% OwnerJul 26Sale0.30298,62889,4393,231,372Jul 26 04:45 PM
open in yahoo | open in reuters | open in google